Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.

Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, Morlock L, Lotan Y, Raj GV, Sagalowsky A, Margulis V, Cadeddu JA, Ross MT, Bentley DR, Kabbani W, Xie XJ, Kapur P, Williams NS, Brugarolas J.

Sci Transl Med. 2012 Jun 6;4(137):137ra75. doi: 10.1126/scitranslmed.3003643.

2.

Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.

Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl DM.

Urol Oncol. 2014 Jan;32(1):43.e23-30. doi: 10.1016/j.urolonc.2013.05.008. Epub 2013 Aug 2.

3.

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.

Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B.

Clin Cancer Res. 2013 Mar 1;19(5):1257-68. doi: 10.1158/1078-0432.CCR-12-2885. Epub 2013 Jan 21.

4.

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue.

Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, Ishkin A, Nikolsky Y, Resau JH, Sigler R, Nickoloff BJ, Webb CP.

J Transl Med. 2012 Jun 18;10:125. doi: 10.1186/1479-5876-10-125.

5.

Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing.

Pavía-Jiménez A, Tcheuyap VT, Brugarolas J.

Nat Protoc. 2014 Aug;9(8):1848-59. doi: 10.1038/nprot.2014.108. Epub 2014 Jul 10.

6.

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.

Clin Cancer Res. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. Epub 2013 May 8.

7.

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST.

Clin Cancer Res. 2010 Jan 1;16(1):141-53. doi: 10.1158/1078-0432.CCR-09-1385. Epub 2009 Dec 22.

8.

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM.

Neoplasia. 2009 Sep;11(9):910-20.

9.

Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.

Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G.

Cancer Res. 1997 Nov 1;57(21):4803-10.

10.

Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.

Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B.

Clin Genitourin Cancer. 2013 Jun;11(2):128-33. doi: 10.1016/j.clgc.2012.12.001. Epub 2013 Jan 17.

PMID:
23332872
11.

Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.

Yamamoto K, Mizutani Y, Nakanishi H, Fujiwara J, Ishida H, Toiyama D, Abe K, Hayashi I, Okada K, Kawauchi A, Mizuno M, Yoshida J, Miki T.

Int J Oncol. 2008 Sep;33(3):565-71.

PMID:
18695887
12.

Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model.

Hillman GG, Wang Y, Che M, Raffoul JJ, Yudelev M, Kucuk O, Sarkar FH.

BMC Cancer. 2007 Jan 9;7:4.

13.

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.

Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP.

J Transl Med. 2012 Dec 10;10:245. doi: 10.1186/1479-5876-10-245.

14.

Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, Macaulay VM.

Mol Cancer Ther. 2009 Jun;8(6):1448-59. doi: 10.1158/1535-7163.MCT-09-0101. Epub 2009 Jun 9.

15.

Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.

Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R, Shi MM.

J Hepatol. 2012 Mar;56(3):595-601. doi: 10.1016/j.jhep.2011.09.017. Epub 2011 Oct 23.

PMID:
22027573
16.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
17.

Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.

Yuen JS, Sim MY, Sim HG, Chong TW, Lau WK, Cheng CW, Ong RW, Huynh H.

Int J Oncol. 2012 Aug;41(2):712-20. doi: 10.3892/ijo.2012.1494. Epub 2012 May 23.

PMID:
22641227
18.

The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA, Tsao MS.

Clin Cancer Res. 2011 Jan 1;17(1):134-41. doi: 10.1158/1078-0432.CCR-10-2224. Epub 2010 Nov 16.

19.

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R.

Oncologist. 2010;15(4):428-35. doi: 10.1634/theoncologist.2009-0178. Epub 2010 Mar 23.

20.

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4538-46.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk